Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide
combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A
randomized, controlled, double-blind, single center.Treatment cycle is 6 months,